CE-245677
CE-245677 is a novel investigational drug that is currently under research for its potential therapeutic applications. It is primarily being studied for its effects on neurological disorders, particularly those involving neuroinflammation and neurodegeneration.
Mechanism of Action
CE-245677 is believed to function as a selective inhibitor of a specific enzyme involved in the inflammatory pathway. By inhibiting this enzyme, CE-245677 may reduce the production of pro-inflammatory cytokines, which are implicated in the pathogenesis of various neurological conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Pharmacokinetics
The pharmacokinetic profile of CE-245677 is characterized by its oral bioavailability, moderate protein binding, and hepatic metabolism. The drug is primarily metabolized by the liver, with metabolites being excreted via the renal route. The elimination half-life of CE-245677 is approximately 12 hours, allowing for potential once-daily dosing.
Clinical Trials
CE-245677 is currently in Phase II clinical trials. Preliminary results have shown promise in reducing markers of inflammation in patients with mild to moderate Alzheimer's disease. Further studies are ongoing to evaluate its efficacy and safety in a larger cohort of patients.
Adverse Effects
The most commonly reported adverse effects of CE-245677 include mild gastrointestinal disturbances, headache, and dizziness. These side effects are generally transient and resolve without intervention. However, long-term safety data is still being collected.
Research and Development
The development of CE-245677 is being spearheaded by a collaboration between several academic institutions and pharmaceutical companies. The research is funded by grants from national health organizations and private investors interested in advancing treatments for neurodegenerative diseases.
Also see
Template:Drug development footer
WikiMD neurology
External links
- Comprehensive information from the National Institute of health.
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
